Quinidine hydrochloride monohydrate|6151-40-2|(奎尼丁盐酸盐一水合物)-陌孚医药/Medlife

您当前的位置：

Quinidine hydrochloride monohydrate (Synonyms: 奎尼丁盐酸盐一水合物)

目录号: PC61820 纯度: ≥99%

CAS No. :6151-40-2

商品编号	规格	价格	会员价
PC61820-1mg	1mg	询价	询价
PC61820-100mg	100mg	¥475.00	请登录
PC61820-1mL	1mL	¥522.50	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Quinidine hydrochloride monohydrate
中文别名	奎寧定鹽酸鹽;奎尼丁盐酸盐一水合物;奎尼丁单盐酸盐一水合物;Quinidine Hydrochloride;奎尼丁盐酸盐一水合物
英文名称	Quinidine hydrochloride monohydrate
英文别名	Cinchonan-9-ol,6'-methoxy-, monohydrochloride, monohydrate, (9S)- (9CI);QUINIDINE HYDROCHLORIDE;QUINIDINE HYDROCHLORIDE MONOHYDRATE;QUINIDINE HYDROCHLORIDE MONOHYDRATE CRYSTALLINE;Quinidine monohydrate hydrochloride
Cas No.	6151-40-2
分子式	C₂₀H₂₄N₂O₂^.HCl^.H₂O
分子量	378.89
包装储存	4°C, sealed storage and away from moisture；*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage and away from moisture)；

生物活性	Quinidine hydrochloride monohydrate is an anti-arrythmic agent which is also a potent blocker of K channel with an IC₅₀ of 19.9 μM.
性状	Solid
IC50 & Target[1][2]	Plasmodium

体外研究(In Vitro)

Quinidine hydrochloride monohydrate blocks WT mSlo3 (KCa5.1) channels with an IC50 of 19.9±1.41?μM and Hill slope of 1.15±0.15 (n=7). Again, the potency of inhibition by Quinidine hydrochloride monohydrate is higher for F304Y mSlo3 (IC50 of 2.42±0.60?μM, n=9, P<0.005; Hill slope of 0.98±0.12), but lower with R196Q mSlo3 (IC50 of 38.4±6.77?μM, n=5, P<0.001; Hill slope of 1.05±0.16). The inhibition of F304Y mSlo3 by Quinidine hydrochloride monohydrate is observed to have some time dependence.Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Direct application of Quinidine hydrochloride monohydrate on the sciatic nerve produces a dose-related decrease in amplitude at ascending somato-sensory evoked potential (SSEP) and descending compound muscle action potentials (CMAP) when comparing baseline with other time points, or when comparing the experimental left limb to the right contra-lateral glucose-treated limb. The latencies of SSEPs and CMAP potentials after Quinidine hydrochloride monohydrate applications are increased compare to baseline and the contralateral side.Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature or refrigerated transport.

储存方式

4°C, sealed storage and away from moisture；*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage and away from moisture)；

ClinicalTrial

结构分类

Others

来源

Plants

溶解度数据	体外研究: DMSO : 100 mg/mL(263.93 mM;Need ultrasonic) H₂O : 2.5 mg/mL(6.60 mM;Need ultrasonic) 配制储存液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation